JULIANA FOLLONI FERNANDES

(Fonte: Lattes)
Índice h a partir de 2011
10
Projetos de Pesquisa
Unidades Organizacionais
Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/36 - Laboratório de Pediatria Clínica, Hospital das Clínicas, Faculdade de Medicina

Resultados de Busca

Agora exibindo 1 - 5 de 5
  • conferenceObject
    Hospital Length of Stay and Impact of Readmission in the First 100 Days of Allogeneic Stem Cell Transplantation: Comparison among Alternative Donor in Pediatric and Adult Population
    (2018) KERBAUY, Mariana Nassif; KERBAUY, Lucila Nassif; ESTEVES, Iracema; ROCHA, Juliana DallAgnol; STANZIONE, Renata Leati; RODRIGUES, Morgani; FERNANDES, Juliana Folloni; KUTNER, Jose Mauro; SOBRINHO, Jairo J. N.; MANTOVANI, Luiz Fernando Alves Lima; KERBAUY, Fabio R.; RIBEIRO, Andreza Feitosa; HAMERSCHLAK, Nelson
  • conferenceObject
    Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease in a Single Institution in Brazil. Reproducing Good Results with a Reduced Toxicity Regimen
    (2017) FERNANDES, Juliana Folloni; MANTOVANI, Luiz Fernando Alves Lima; VENANCIO, Angela Mandelli; DORNA, Mayra; PASTORINO, Antonio Carlos; VASCONCELOS, Dewton; NETO, Antonio Condino; MOURA, Ana Carla Augusto; COLLASSANTI, Maria Dulce; ZANICHELLI, Maria Aparecida; CARNEIRO-SAMPAIO, Magda; ROCHA, Vanderson G.; ODONE FILHO, Vicente
  • article 13 Citação(ões) na Scopus
    Haploidentical bone marrow transplantation with post transplant cyclophosphamide for patients with X-linked adrenoleukodystrophy: a suitable choice in an urgent situation
    (2018) FERNANDES, Juliana Folloni; BONFIM, Carmem; KERBAUY, Fabio Rodrigues; RODRIGUES, Morgani; ESTEVES, Iracema; SILVA, Nathalia Halley; AZAMBUJA, Alessandra Prandini; MANTOVANI, Luiz Fernando; KUTNER, Jose Mauro; LOTH, Gisele; KUWAHARA, Cilmara Cristina; BUENO, Clarissa; KONDO, Andrea Tiemi; RIBEIRO, Andreza Alice Feitosa; KOK, Fernando; HAMERSCHLAK, Nelson
    Allogeneic hematopoietic stem cell transplantation (HSCT) is the only treatment that enhances survival and stabilizes neurologic symptoms in X-linked adrenoleukodystrophy (X-ALD) with cerebral involvement, a severe demyelinating disease of childhood. Patients with X-ALD who lack a well-matched HLA donor need a rapid alternative. Haploidentical HSCT using post transplant cyclophosphamide (PT/Cy) has been performed in patients with malignant and nonmalignant diseases showing similar outcomes compared to other alternative sources. We describe the outcomes of transplants performed for nine X-ALD patients using haploidentical donors and PT/Cy. Patients received conditioning regimen with fludarabine 150 mg/m(2) , cyclophosphamide 29 mg/kg and 2 Gy total body irradiation (TBI) with or without antithymocyte globulin. Graft-vs.-host disease prophylaxis consisted of cyclophosphamide 50 mg/kg/day on days +3 and +4, tacrolimus or cyclosporine A and mycophenolate mofetil. One patient had a primary graft failure and was not eligible for a second transplant. Three patients had secondary graft failure and were successfully rescued with second haploidentical transplants. Trying to improve engraftment, conditioning regimen was changed, substituting 2 Gy TBI for 4 Gy total lymphoid irradiation. Eight patients are alive and engrafted (17-37 months after transplant). Haploidentical HSCT with PT/Cy is a feasible alternative for X-ALD patients lacking a suitable matched donor. Graft failure has to be addressed in further studies.
  • conferenceObject
    Salvage Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide for graft failure in children with non-malignant diseases
    (2018) FERNANDES, Juliana Folloni; RIBEIRO, Andreza Alice Feitosa; KERBAUY, Fabio Rodrigues; MANTOVANI, Luiz Fernando; NETTO, Gabriele Zamperlini; VENANCIO, Angela Mandelli; SILVA, Cinthya Correa; KONDO, Andrea Tiemi; COLLASSANTI, Maria Dulce Silveira; ZANICHELLI, Maria Aparecida; VINCE, Carolina Sgarioni Camargo; BRUMATTI, Melina; ODONE FILHO, Vicente; HAMERSCHLAK, Nelson
  • article 14 Citação(ões) na Scopus
    Transplantation of Hematopoietic Stem Cells for Primary Immunodeficiencies in Brazil: Challenges in Treating Rare Diseases in Developing Countries
    (2018) FERNANDES, Juliana Folloni; NICHELE, Samantha; DAUDT, Liane E.; TAVARES, Rita B.; SEBER, Adriana; KERBAUY, Fabio R.; KOLISKI, Adriana; LOTH, Gisele; VIEIRA, Ana K.; DARRIGO-JUNIOR, Luiz G.; ROCHA, Vanderson; GOMES, Alessandra A.; COLTURATO, Vergilio; MANTOVANI, Luiz F.; RIBEIRO, Andreza F.; RIBEIRO, Lisandro L.; KUWAHARA, Cilmara; RODRIGUES, Ana L. M.; ZECCHIN, Victor G.; COSTA-CARVALHO, Beatriz T.; CARNEIRO-SAMPAIO, Magda; CONDINO-NETO, Antonio; FASTH, Anders; GENNERY, Andrew; PASQUINI, Ricardo; HAMERSCHLAK, Nelson; BONFIM, Carmem
    The results of hematopoietic stem cell transplant (HSCT) for primary immunodeficiency diseases (PID) have been improving over time. Unfortunately, developing countries do not experience the same results. This first report of Brazilian experience of HSCT for PID describes the development and results in the field. We included data from transplants in 221 patients, performed at 11 centers which participated in the Brazilian collaborative group, from July 1990 to December 2015. The majority of transplants were concentrated in one center (n=123). The median age at HSCT was 22months, and the most common diseases were severe combined immunodeficiency (SCID) (n=67) and Wiskott-Aldrich syndrome (WAS) (n=67). Only 15 patients received unconditioned transplants. Cumulative incidence of GVHD grades II to IV was 23%, and GVHD grades III to IV was 10%. The 5-year overall survival was 71.6%. WAS patients had better survival compared to other diseases. Most deaths (n=53) occurred in the first year after transplantation mainly due to infection (55%) and GVHD (13%). Although transplant for PID patients in Brazil has evolved since its beginning, we still face some challenges like delayed diagnosis and referral, severe infections before transplant, a limited number of transplant centers with expertise, and resources for more advanced techniques. Measures like newborn screening for SCID may hasten the diagnosis and ameliorate patients' conditions at the moment of transplant.